Tarsus Pharmaceuticals, Inc. TARS · Stock Open Tarsus Pharmaceuticals, Inc. in new tab
Tarsus Pharmaceuticals, Inc. Analysis (TARS)
Is Tarsus Pharmaceuticals, Inc. a good investment? Tarsus Pharmaceuticals, Inc. (TARS) is currently trading at 61.32 USD. Market analysts have a consensus price target of 94.44 USD. This suggests a potential upside from current levels.
Earnings Schedule: Tarsus Pharmaceuticals, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 1.66.
Investor FAQ
Does Tarsus Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.11.
Company Profile
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Community Discussion